This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Array BioPharma
ClinicalTrials.gov Identifier:
NCT01719380
First received: October 30, 2012
Last updated: July 21, 2017
Last verified: July 2017
October 30, 2012
July 21, 2017
November 2012
October 31, 2015   (Final data collection date for primary outcome measure)
  • Incidence rate of dose-limiting toxicities [ Time Frame: 1.5 years ]
    Phase I
  • Progression free survival [ Time Frame: 2.5 years ]
    Phase II
Same as current
Complete list of historical versions of study NCT01719380 on ClinicalTrials.gov Archive Site
  • Incidence and severity of adverse events [ Time Frame: 2.5 years ]
  • Plasma concentration [ Time Frame: 1.5 years ]
  • Overall response rate [ Time Frame: 2.5 years ]
  • Duration of response [ Time Frame: 2.5 years ]
  • Time to response [ Time Frame: baseline, 2 years ]
  • Progression free survival [ Time Frame: 1.5 years ]
    Phase Ib
  • Overall survival [ Time Frame: 3 years ]
    Phase II
  • Baseline molecular status of potential predictive markers of tumor response or resistance [ Time Frame: 2.5 years ]
Same as current
Not Provided
Not Provided
 
Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer
A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer
This study will assess the safety and efficacy of LGX818 when combined with cetuximab or combined with cetuximab and BYL719 in patients with BRAF mutant metastatic colorectal cancer
Not Provided
Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
Colorectal Cancer
  • Drug: LGX818
  • Drug: Cetuximab
  • Drug: BYL719
  • Experimental: LGX818 + cetuximab
    Interventions:
    • Drug: LGX818
    • Drug: Cetuximab
  • Experimental: LGX818 + BYL719 + cetuximab
    Interventions:
    • Drug: LGX818
    • Drug: Cetuximab
    • Drug: BYL719
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
150
March 1, 2018
October 31, 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Metastatic colorectal cancer
  • Progression after at least one prior standard of care regimen or be intolerant to irinotecan-based regimens
  • Life expectancy ≥ 3 months
  • ECOG performance status ≤ 2

Exclusion Criteria:

  • Symptomatic or untreated leptomeningeal disease
  • Symptomatic brain metastasis
  • Patients with clinically manifested diabetes
  • Acute or chronic pancreatitis
  • Clinically significant cardiac disease

Other protocol-defined inclusion/exclusion criteria may apply.

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Australia,   Belgium,   Canada,   France,   Germany,   Italy,   Japan,   Korea, Republic of,   Netherlands,   Norway,   Spain,   United States
 
 
NCT01719380
CLGX818X2103
2012-002138-35 ( EudraCT Number )
Not Provided
Not Provided
Not Provided
Array BioPharma
Array BioPharma
Not Provided
Study Director: Array BioPharma 303-381-6604
Array BioPharma
July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP